Clinical trials: Cholangiocarcinomas
Cholangiocarcinoma
Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations
This study tests whether adding becotatug vedotin (EGFR-ADC) to standard chemotherapy plus immunotherapy improves outcomes compared to chemotherapy plus immunotherapy alone as first-line treatment for patients with advanced or…
- Trial name
- NCT07598318
- Testing
- Becotatug Vedotin, Pucotenlimab, Gemcitabine
- Volunteers
- 164 people
- Sponsor
- Sir Run Run Shaw Hospital
Cholangiocarcinoma
Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement
This is a phase 2 study to investigate the efficacy and safety of Pemigatinib in treating patients with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 rearrangement who have failed at least 1…
- Trial name
- NCT04256980
- Testing
- Pemigatinib
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Advanced Cholangiocarcinoma
Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron
This is an open-label, single-arm, multicenter Phase II safety and efficacy study of combination therapy with pembrolizumab and Sylatron (Peginterferon alpha-2b) in patients with advanced cholangiocarcinoma who have progressed on…
- Trial name
- NCT02982720
- Testing
- Pembrolizumab, Sylatron
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Aiwu Ruth He, MD
Hepatocellular Carcinoma, Cholangiocarcinoma
Liver Embolization Approaches for Tumor Management
The goal of this evaluate short, medium and long term outcome of the different embolization techniques in patients with primary and secondary hepatic tumors.
- Conditions
- Hepatocellular Carcinoma, Cholangiocarcinoma, Metastatic Colon Cancer, Metastatic Cancer
- Trial name
- LEATUM (NCT05714124)
- Testing
- Embolization
- Where
- Italy
- Volunteers
- 580 people
- Sponsor
- IRCCS San Raffaele
Intrahepatic Cholangiocarcinoma
PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery
SHR-1210 is a humanized anti-PD-1 Immunoglobulin G4 (IgG4) monoclonal antibody. This is an open- label,single center,non-randomized ,single arm exploratory study .
- Trial name
- NCT04295317
- Testing
- PD-1 blocking antibody SHR-1210, Capecitabine
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Shanghai Zhongshan Hospital
Cholangiocarcinoma
Mechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver Injury
The goal of this clinical trial is to learn if spirulina can help protect the liver and promote recovery after partial hepatectomy (surgery to remove part of the liver).
- Trial name
- NCT07263217
- Testing
- Spirulina, Maltodextrin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
This phase II trial is studying how well bortezomib works as first-line systemic therapy in treating patients with unresectable locally advanced or metastatic adenocarcinoma (cancer) of the bile duct or gallbladder.
- Conditions
- Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Advanced Adult Primary Liver Cancer, Gastrointestinal Cancer
- Trial name
- NCT00085410
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Cholangiocarcinoma
S-1 in Combination With Abraxane in Treating Cholangiocarcinoma
This phase II study was designed to evaluate the efficacy and safety of S-1 plus Abraxane as second-line treatment for cholangiocarcinoma.
- Trial name
- NCT01963325
- Testing
- S-1 plus Abraxane
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Yuhong Li
Advanced Malignant Solid Tumor, Solid Tumor Cancer
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
The goal of this clinical trial is to learn about what doses of PLT012 are safe to use in adults with advanced cancers in solid tumors. It will also learn about how effective different doses of PLT012 are in treating cancer.
- Trial name
- NCT07337525
- Testing
- PLT012
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Pilatus Biosciences Inc
Pancreas Cancer, Cholangiocarcinoma
Radiofrequency Ablation for Biliopancreatic Malignancy
This phase-2 study aims to evaluate feasibility, safety and efficacy of thermal ablation of biliary obstructive malignancies by means of radiofrequency ablation (RFA, ELRA, StarMed) during endoscopic retrograde…
- Conditions
- Pancreas Cancer, Cholangiocarcinoma, Obstructive Jaundice
- Trial name
- IGNITE-1 (NCT02468076)
- Testing
- Radiofrequency ablation (StarMed)
- Where
- Belgium
- Volunteers
- 18 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Advanced Solid Tumor, Metastatic Solid Tumor
Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)
The purpose of the present study is to determine the safety, tolerability, and efficacy of WM-A1-3389 in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancer…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Lung Cancer, Colorectal Cancer
- Trial name
- NCT05872867
- Testing
- WM-A1-3389, Pembrolizumab
- Where
- 2 sites in South Korea
- Volunteers
- 54 people
- Sponsor
- Wellmarker Bio
Cholangiocarcinoma, Ampullary Carcinoma
Endobiliary RFA for Unresectable Malignant Biliary Strictures
Only a small proportion of patients with cholangiocarcinoma or ampullary carcinoma are suitable for surgical resection. The endoscopic or percutaneous transhepatic biliary drainage is accepted approaches for the relief of…
- Trial name
- NCT01844245
- Testing
- Radiofrequency ablation (RFA)
- Where
- 6 sites in China
- Volunteers
- 174 people
- Sponsor
- Bing Hu
Cholangiocarcinoma
Validation of the Proteomic Profiling as a Diagnostic Test for Extra-hepatic Cholangiocarcinoma
The study aims to valide a proof of a concept of the proteomic profiling as a diagnostic tool for bile duct stenosis suspicious of cholangiocarcinoma.
- Trial name
- PROFI-CHOL (NCT06780553)
- Testing
- Proteomic profiling
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Bordeaux
Jaundice, Obstructive, Klatskin Tumor
Process Optimization of Preoperative Biliary Drainage in Patients With Malignant Obstructive Jaundice
The purpose of this study is to evaluate the safety and effectiveness of different methods of preoperative biliary drainage in patients with extrahepatic bile duct neoplasms with obstructive jaundice (hilar cholangiocarcinoma…
- Trial name
- NCT03527875
- Testing
- PTBD group, ENBD group, EBS group
- Volunteers
- 564 people
- Sponsor
- Shanghai Zhongshan Hospital
Intrahepatic Cholangiocarcinoma
SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
The study planned to evaluate the benefit of applying Selective Internal Radiation Therapy (SIRT) using SIR-Spheres Y-90 resin microspheres prior to receiving systemic chemotherapy treatment (cisplatin-gemcitabine, or CIS-GEM) in…
- Trial name
- SIRCCA (NCT02807181)
- Testing
- Cisplatin-gemcitabine, Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)
- Where
- 23 sites in United States, Australia and 6 more
- Volunteers
- 89 people
- Sponsor
- Sirtex Medical
Intrahepatic Cholangiocarcinoma
Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
The objective of this study is to evaluate the efficacy and safety of Lenvatinib plus Sintilimab in patients with advanced liver cancer progressed after treatment with immune checkpoint inhibitors.
- Trial name
- NCT05010681
- Testing
- Sintilimab, Lenvatinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Intrahepatic Cholangiocarcinoma
A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma
Compare the efficacy of adjuvant chemotherapy with Cisplatin or Carboplatin and Gemcitabine versus Gemcitabine in patients with resected or ablated intra-hepatic cholangiocarcinoma.
- Trial name
- NCT03081039
- Testing
- Carboplatin, Cisplatin, Gemcitabine
- Where
- United States
- Sponsor
- University of Louisville
Cholangiocarcinoma, Pancreatic Cancer
T-EUS for Gastrointestinal Disorders: A Multicenter Registry
The purpose of this registry is to record information and evaluate the impact of Endoscopic Ultrasound (EUS) Guided Endoscopic retrograde cholangiopancreatography (ERCP) on the management of pancreatico-biliary disorders.
- Conditions
- Cholangiocarcinoma, Pancreatic Cancer, Bile Duct Cancer, Biliary Stricture
- Trial name
- EUSERCPReg (NCT01522573)
- Testing
- EUS guided ERCP
- Where
- 2 sites in United States, Brazil
- Volunteers
- 1,000 people
- Sponsor
- Weill Medical College of Cornell University
Morbid Obesity, Vertical Sleeve Gastrectomy
Metabolic Syndrome, Bile Acids, Hepatocellular Carcinoma and Cholangiocarcinoma
Increasing rates of highly malignant hepatocellular carcinoma (HCC) and biliary tract cancers (GBTC) observed in Western populations may be related to obesogenic lifestyle factors and their metabolic consequences, such as…
- Conditions
- Morbid Obesity, Vertical Sleeve Gastrectomy, Metabolic Syndrome, Hepatocellular Carcinoma
- Trial name
- METSLIVER (NCT02730611)
- Where
- France
- Volunteers
- 124 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Biliary Tract Carcinoma, Radiotherapy
Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma
[Study objectives] To evaluate the efficacy and safety of the combined treatment of radiotherapy and endoscopic intraductal radiofrequency ablation in patients with locoregional extrahepatic cholangiocarcinoma.
- Conditions
- Biliary Tract Carcinoma, Radiotherapy, Radio-frequency Ablation
- Trial name
- NCT06168292
- Testing
- ID-RFA and Radiotherapy
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- National Cancer Center, Korea
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.